| 1 |
34072570 | PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells. | 2021 May 29 |
6 |
| 2 |
30761258 | Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. | 2019 Feb |
1 |
| 3 |
31523192 | Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. | 2019 |
3 |
| 4 |
30425575 | Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways. | 2018 |
1 |
| 5 |
26546044 | Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. | 2016 Jan 28 |
2 |
| 6 |
26711788 | MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. | 2016 Jun |
1 |
| 7 |
27129180 | Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. | 2016 Jul 5 |
4 |
| 8 |
27681866 | A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). | 2016 Dec |
1 |
| 9 |
27688096 | The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. | 2016 Oct |
1 |
| 10 |
27853648 | Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. | 2016 |
2 |
| 11 |
25559745 | Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. | 2015 Aug |
2 |
| 12 |
25579168 | Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. | 2015 Feb |
1 |
| 13 |
25614335 | Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma. | 2015 Feb 15 |
1 |
| 14 |
26556863 | Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells. | 2015 Dec 22 |
2 |
| 15 |
25219752 | The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. | 2014 Nov 15 |
1 |
| 16 |
23243060 | Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. | 2013 Feb |
1 |
| 17 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
1 |
| 18 |
22190165 | Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. | 2012 Mar |
1 |
| 19 |
21407223 | Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. | 2011 Mar 15 |
1 |
| 20 |
21525937 | Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. | 2011 Apr 28 |
1 |
| 21 |
20428777 | Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. | 2010 Jun |
2 |
| 22 |
20596679 | Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. | 2010 Aug |
2 |
| 23 |
19698189 | Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. | 2009 Aug 24 |
6 |
| 24 |
19703270 | Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? | 2009 Aug 24 |
2 |
| 25 |
18787411 | Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. | 2008 Oct |
5 |
| 26 |
18819900 | [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. | 2008 Aug |
1 |
| 27 |
17548474 | The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. | 2007 Aug |
2 |
| 28 |
17704426 | Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. | 2007 Aug 20 |
1 |